Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526638 | 0.86 | NOS1 (0.40) | NOS1NOS3NOS2LMNAGAA | |
| SCHEMBL141446 | 0.83 | ALDH1A1 (0.53) | CYP2C19ALDH1A1HPGDMMP8LMNA | |
| SCHEMBL28186389 | 0.81 | ALDH1A1 (0.50) | CYP2C19ALDH1A1HPGDMMP8LMNA | |
| Ethane SCHEMBL9181718 | 0.81 | ALDH1A1 (0.50) | CYP2C19ALDH1A1HPGDMMP8LMNA | |
| SCHEMBL8800602 | 0.81 | ALDH1A1 (0.50) | CYP2C19ALDH1A1HPGDMMP8LMNA | |
| Ammonia Solution, Strong SCHEMBL28791130 | 0.81 | ALDH1A1 (0.50) | CYP2C19ALDH1A1HPGDMMP8LMNA | |
| SCHEMBL27800508 | 0.81 | NOS1 (0.40) | NOS1NOS3NOS2LMNAGAA | |
| SCHEMBL1661987 | 0.80 | CYP1A2 (0.41) | CYP1A2CYP2C9CYP2C19HTTALDH1A1 | |
| SCHEMBL9847861 | 0.78 | CA1 (0.35) | CYP1A2CYP2C9CYP2C19HTTMMP8 | |
| SCHEMBL3953356 | 0.78 | CYP1A2 (0.38) | CYP1A2CYP2C9CYP2C19HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001072704-A1 | AZETIDINONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A METHOD FOR PRODUCING 1-β-ALKYL AZETIDINONE USING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2001-10-04 | — | — | WO | claimed |
| US-9834527-B2 | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2017-12-05 | — | — | US | disclosed |
| EP-3027611-B1 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFI A, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-07-26 | — | — | EP | disclosed |
| EP-3027611-A1 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFI A, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-06-08 | — | — | EP | disclosed |
| US-20160137618-A1 | Macrocyclic Urea Derivatives as Inhibitors of TAFIa, Their Preparation and Their Use as Pharmaceuticals | SANOFI (FR) | 2016-05-19 | — | — | US | disclosed |
| CN-105263928-A | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as medicaments | SAI NUOFEI | 2016-01-20 | — | — | CN | disclosed |
| WO-2014198620-A1 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFIA, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-12-18 | — | — | WO | disclosed |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | SALTER-CID LUISA M (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | SALTER-CID LUISA M (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | SALTER-CID LUISA M (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2001072704-A1 | AZETIDINONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A METHOD FOR PRODUCING 1-β-ALKYL AZETIDINONE USING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2001-10-04 | — | — | WO | disclosed |
| EP-0546742-B1 | 4-(1,1-Dialkoxycarbonyl-alkyl)azetidin-2-one derivatives and synthesis of 4-(1-carboxy-alkyl)azetidin-2-one derivatives therefrom | TAKASAGO PERFUMERY CO LTD (JP) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000066557-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-09 | — | — | WO | disclosed |
| US-5574152-A | 4-(1,1-dialkoxycarbonylalkyl) azetidin-2-one derivative and process for producing 4-(1-carboxyalkyl) azetidin-2-one derivative using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1996-11-12 | — | — | US | disclosed |
| US-5371214-A | 4-(1,1-dialkoxycarbonylalkyl)azetidin-2-one derivative and process for producing 4-(1-carboxyalkyl)azetidin-2-one derivative using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-12-06 | — | — | US | disclosed |
| EP-0546742-A1 | 4-(1,1-Dialkoxycarbonyl-alkyl)azetidin-2-one-derivatives and synthesis of 4-(1-carboxy-alkyl)azetidin-2-one derivatives therefrom | Takasago International Corporation (JP) | 1993-06-16 | — | — | EP | disclosed |
| CN-1008817-B | Process for preparing fluoroallylamine derivatives | MERRELL DOW PHARMACEVTICALS IN (US) | 1990-07-18 | — | — | CN | disclosed |
| EP-0168013-B1 | FLUOROALLYLAMINE DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4699928-A | ANTIDEPRESSANTS, TREATMENT OF PARKINSON'S DISEASE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-10-13 | — | — | US | disclosed |
| EP-0168013-A1 | Fluoroallylamine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137618-A1 | Macrocyclic Urea Derivatives as Inhibitors of TAFIa, Their Preparation and Their Use as Pharmaceuticals | TFPI, TFPI2, F12 | CYP1A2 731/4885CYP2C9 375/4885CYP2C19 399/4885 |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | VCAM1, AOC2, AOC1 | CYP1A2 2016/4885CYP2C9 3363/4885CYP2C19 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.